US › Healthcare

Lyra Therapeutics Inc (LYRA)

US · Healthcare · Biotechnology

$0.470.00%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$7,000

Revenue YoY

-96.7%

Net profit

$-7.0M

Profit YoY

+36.7%

EPS

$-3.92

Net margin

-99,300.0%

Key statistics

Market cap

$843,068

Forward P/E

0.0

P/B

7.10

Book value

$-6.04

EPS (TTM)

$-18.62

52-week high

$8.75

52-week low

$0.00

50-day MA

$0.61

200-day MA

$1.78

Beta

0.70

Analyst view

Analysts rate Lyra Therapeutics Inc a hold (0 buy, 4 hold, 0 sell out of 4) with an average price target of $16.00.

Shareholding

Insiders

0.62%

Institutions

12.53%

Largest institutional holders

Fund	Stake
Sabby Management LLC	5.86%
Comerica Bank	0.00%
Global Retirement Partners, LLC.	0.00%
EverSource Wealth Advisors, LLC	0.00%
Bryn Mawr Trust Company	0.00%
BlackRock Inc	0.00%
Tower Research Capital LLC	0.00%
Citadel Advisors Llc	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lyra Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.